scholarly journals Type 1 Papillary Renal Cell Carcinoma Presenting as an Infected Benign Renal Cyst: an Uncommon Presentation

2018 ◽  
Vol 9 (2) ◽  
pp. 265-267
Author(s):  
Chanchal Rana ◽  
Manoj Kumar ◽  
Suresh Babu ◽  
Atin Singhai ◽  
H. Agarwal
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Cyst ◽  
Papillary Renal Cell Carcinoma ◽  
Uncommon Presentation

scholarly journals Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines

2021 ◽  
Author(s):  
Youfeng Yang ◽  
Christopher J. Ricketts ◽  
Cathy D. Vocke ◽  
J. Keith Killian ◽  
Hesed M. Padilla‐Nash ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Renal Cell ◽  
Carcinoma Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Renal Cell Carcinoma Cell ◽  
Carcinoma Cell Lines

Abstract 4221: Anti-Tumor activity of the multityrosine kinase inhibitor dasatinib in type 1 papillary renal cell carcinoma

2020 ◽  
Author(s):  
Roma Pahwa ◽  
Janhavi Dubhashi ◽  
Abhigya Giri ◽  
Craig Thomas ◽  
Michele Ceribelli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Papillary Renal Cell Carcinoma ◽  
Anti Tumor Activity

scholarly journals Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2

2019 ◽  
Vol 37 (10) ◽  
pp. 721-726 ◽  
Author(s):  
Emily C.L. Wong ◽  
Richard Di Lena ◽  
Rodney H. Breau ◽  
Frederic Pouliot ◽  
Antonio Finelli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Prognostic Predictor

scholarly journals Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma

2009 ◽  
Vol 15 (4) ◽  
pp. 1162-1169 ◽  
Author(s):  
Tobias Klatte ◽  
Allan J. Pantuck ◽  
Jonathan W. Said ◽  
David B. Seligson ◽  
Nagesh P. Rao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Tumor Profiling

Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4503-4503
Author(s):  
B. T. Teh ◽  
X. J. Yang ◽  
M. Tan ◽  
H. L. Kim ◽  
W. Stadler ◽  
...  
Keyword(s):  
Gene Expression ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Comparative Genomic ◽  
Low Grade ◽  
Class 1

4503 Background: Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphological classification of PRCC into Type 1 and Type 2 tumors has been recently proposed, but its biological relevance remains uncertain. Methods: We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analysis. Comparative genomic microarray analysis (CGMA) was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples, with 15 independent tumors. Results: We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histological subtypes: Type 1, low-grade Type 2 and mixed Type 1/low-grade Type 2 tumors. The second class, with poor survival, corresponded to high-grade Type 2 tumors (n = 11). Dysregulation of G1/S and G2/M checkpoint genes were found in Class 1 and Class 2 tumors respectively, alongside characteristic chromosomal aberrations. We identified a 7-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in Class 1 tumors, and of topoisomerase IIα in Class 2 tumors. Conclusions: We report two molecular subclasses of PRCC, which are biologically and clinically distinct, which may be readily distinguished in a clinical setting. This may also have therapeutic implications. No significant financial relationships to disclose.

MP36-01 CAN MULTIPHASE CT SCAN DISTINGUISH BETWEEN TYPE 1 AND TYPE 2 PAPILLARY RENAL CELL CARCINOMA? A RETROSPECTIVE ANALYSIS

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Michelle McDonald ◽  
Hak Lee ◽  
Vipulkumar Dadhania ◽  
Song Wang ◽  
Ryan Kopp ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Ct Scan ◽  
Cell Carcinoma ◽  
Retrospective Analysis ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Multiphase Ct

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

2017 ◽  
Vol 87 ◽  
pp. 147-163 ◽  
Author(s):  
Patrick Schöffski ◽  
Agnieszka Wozniak ◽  
Bernard Escudier ◽  
Piotr Rutkowski ◽  
Alan Anthoney ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Disease Control ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma

scholarly journals Approach to Complex Renal Cysts: A Single Center Experience

2021 ◽  
Author(s):  
Nadir Kalfazade ◽  
Ekrem Güner
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Cyst ◽  
Renal Cysts ◽  
Papillary Renal Cell Carcinoma ◽  
Lesion Size ◽  
Cell Renal Cell Carcinoma ◽  
Study Results ◽  
The Mean

Objective: Our objective in this study was to present the data for patients followed-up and underwent surgery due to complex renal cyst using Bosniak classification system. Method: Data of all patients followed-up or underwent surgery via open / minimal invasive methods due to complex renal cyst in our clinic between 2016 and 2019 were retrospectively evaluated. Bosniak category IIF and higher lesions were included in the study. Results: A total of 83 patients were included in the study. The mean age of the patients was 52 ±10.1 years and 40 (48.2%) were male and 43 (51.8%) were female. 53 (63.9%) patients had Bosniak IIF, 18 (21.7%) patients had Bosniak III and 12 (14.5%) patients had Bosniak IV lesions. Mean lesion size was 54±27.4 mm. Surgery was performed in a total of 41 (49.4%) patients. Based on final pathology result, while benign pathologies were detected in 13 (31.7%) patients, clear cell renal cell carcinoma was detected in 22 (53.7%) patients and papillary renal cell carcinoma in 6 (14.6%) patients. Malignity rates were detected as 18.9%, 44.4% and 83.3% in Bosniak IIF, III and IV lesions respectively. While the mean lesion size of patients who had benign pathology were 64.6±18.4 mm, mean lesion size of patients with malign pathology were 58.3±29.7 mm (p =.41). Conclusion: Progression is an important malignity finding in Bosniak IIF lesions. An important amount of especially Bosniak III lesions is overtreated. Thus, active surveillance is a treatment which should be considered in these patients. More comprehensive prospective randomized studies are needed.

Evaluation of tumor-associated macrophages as a prognostic indicator in patients with papillary renal cell carcinoma.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 372-372
Author(s):  
G. C. Hutterer ◽  
T. F. Chromecki ◽  
R. Zigeuner ◽  
T. Klatte ◽  
K. Kampel-Kettner ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Size ◽  
Renal Cell ◽  
Vascular Invasion ◽  
Papillary Renal Cell Carcinoma ◽  
Favorable Outcome ◽  
Low Grade ◽  
Tumor Associated Macrophages

372 Background: Prognostic indicators in papillary renal cell carcinoma (PRCC) are not well defined. We evaluated the prognostic relevance of tumor-associated macrophages (TAM) in patients with PRCC. Methods: PRCC specimens were re-evaluated by one blinded pathologist (SM), with respect to pT-classification (TNM 2002), nodal status, Fuhrman grade (I-IV), tumor size, subtype (type 1 or 2), tumor necrosis, and presence of TAM. Presence of TAM was associated with pathological parameters (chi-square and fisher's exact tests). Impact of TAM on cancer-specific survival (CSS) was assessed (Kaplan-Meier method and log-rank test). A multivariate regression analysis including pT-stage, grade, vascular invasion, necrosis, tumor size, papillary subtype and TAM was performed with respect to CSS. Results: 177 patients operated for PRCC from 1984 to 2006, were evaluated. Presence of TAM was noted in 112/177 (63%) tumors and was significantly associated with favorable pathological parameters: low pT-classification (pT1a/b: 71/90, 79%; pT2: 14/31, 45%; pT3a/b: 27/56, 48%; p<0.001), node negative tumors (Nx/pN0: 111/170, 65% vs. pN1/2: 1/7, 14%; p=0.01), low grade (G1: 35/45, 78%; G2: 67/110, 61%; G3: 10/22, 45%; p=0.025), absence of vascular invasion (V0: 106/153, 69% vs. V1/2: 6/24, 25%; p<0.001), and papillary subtype (type 1: 64/87, 74% vs. 48/89, 54%; p=0.007), respectively. Median follow-up was 68.3 months. Five-year CSS probabilities for patients with TAM-positive tumors were 93.5%, compared with 72.5% in patients with TAM-negative tumors (p<0.001). Median survival was not reached in both groups. Multivariate analysis revealed node positive tumors (HR=2.4, 95%CI=1.1-5.0; p=0.025), distant metastases (HR=8.7, 95%CI=2.6-29.3; p<0.001), and tumor size (HR=1.2, 95%CI=1.0-1.3; p=0.03) as independent predictors of death from PRCC, whereas presence of TAM was independently associated with favorable outcome (HR=0.3, 95%CI=0.1-0.9, p=0.026). Conclusions: Presence of TAM was independently associated with a favorable outcome in patients with PRCC and was shown to reduce the risk of death from cancer by 66%. Presence of TAM should therefore be part of routine pathology reporting in PRCC. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document